Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Norprolac; Belgium: Norprolac; Cyprus: Norprolac; Czech Republic: Norprolac; Denmark: Norprolac; Finland: Norprolac; France: Norprolac; Germany: Norprolac; Greece: Norprolac; Hungary: Norprolac; Ireland: Norprolac; Luxembourg: Norprolac; Netherlands: Norprolac; Poland: Norprolac; Portugal: Norprolac; Slovakia: Norprolac; Slovenia: Norprolac; Spain: Norprolac; Sweden: Norprolac; UK: Norprolac.

North America

Canada: Norprolac.

Latin America

Mexico: Norprolac.

Drug combinations


Quinagolide: C~20~H~33~N~3~O~3~S. Mw: 395.56. (±)-N,N-Diethyl-N’-[(3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl]sulfamide. CAS-87056-78-8; CAS-94424-50-7 (hydrochloride).

Pharmacologic Category

Hormones and Synthetic Substitutes; Pituitary. Anti-hyperprolactinemic Agent, Dopamine (D~2~) Agonist. (ATC-Code: G02CB04).

Mechanism of action

Selective dopamine D~2~ receptor agonist. Inhibits lactotroph cells in anterior pituitary gland which synthesize and secrete prolactin.

Therapeutic use


Pregnancy and lactiation implications

No embryotoxic or teratogenic effects in animals. Discontinue use with confirmed pregnancy unless continuation medically necessary. Not recommended in nursing women (by inhibiting prolactin secretion, quinagolide suppresses lactation).

Unlabeled use


Hypersensitivity to quinagolide or any component of the formulation. Hepatic/renal impairment.

Warnings and precautions

Use with caution in women of childbearing age. Use caution when discontinuing therapy in patients who become pregnant. Use may be associated with frequent (but transient) nausea and vomiting early in therapy. Hypotensive episodes with syncope may occur with onset of therapy. Risk of sudden sleep onset and somnolence (especially in Parkinson’s disease). Use with caution in prior psychotic disorders.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart